Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Diffuse Large B Cell Lymphoma，DLBCL”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT02082977
What this trial is testing

Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

Who this might be right for
CancerNeoplasms
GlaxoSmithKline 41
Early research (Phase 1)Ended earlyNCT02702141
What this trial is testing

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaDLBCLDiffuse Large B-cell Lymphoma+1 more
Seagen Inc. 44
Testing effectiveness (Phase 2)Study completedNCT04438005
What this trial is testing

ICP-022 in Patients With R/R DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. 3
Very early researchLooking for participantsNCT05800405
What this trial is testing

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center 9
Testing effectiveness (Phase 2)Looking for participantsNCT03356054
What this trial is testing

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Who this might be right for
DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland 37
Testing effectiveness (Phase 2)UnknownNCT01670370
What this trial is testing

Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.

Who this might be right for
Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University 60
Testing effectiveness (Phase 2)Study completedNCT04323657
What this trial is testing

TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Non Hodgkin LymphomaAcute Lymphoblastic LeukemiaDiffuse Large B Cell Lymphoma+3 more
TCR2 Therapeutics 6
Testing effectiveness (Phase 2)Looking for participantsNCT06701357
What this trial is testing

CR-CHOP+X in Previously Untreated DEL

Who this might be right for
DLBCL
Ruijin Hospital 49
Large-scale testing (Phase 3)UnknownNCT01277172
What this trial is testing

TREatment of degeNerative and Neoplastic Diseases With Rituximab

Who this might be right for
Diffuse Large B Cell Lymphoma
Probiomed S.A. de C.V. 54
Not applicableNot Yet RecruitingNCT07472621
What this trial is testing

Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Henan Cancer Hospital 20
Not applicableStudy completedNCT01606605
What this trial is testing

Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
Samsung Medical Center 350
Early research (Phase 1)WithdrawnNCT06290622
What this trial is testing

PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaLymphoma, B-CellLymphoma, Follicular
University of Alabama at Birmingham
Testing effectiveness (Phase 2)WithdrawnNCT00829205
What this trial is testing

Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Who this might be right for
Lymphoma
Cancer Research UK
Large-scale testing (Phase 3)UnknownNCT03213977
What this trial is testing

R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
Fujian Medical University 475
Testing effectiveness (Phase 2)Ended earlyNCT03298412
What this trial is testing

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

Who this might be right for
High-risk Diffuse Large B-cell Lymphoma
Amgen 10
Not applicableLooking for participantsNCT07057765
What this trial is testing

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

Who this might be right for
DLBCL - Diffuse Large B Cell LymphomaMarkers of Inflammation
Ain Shams University 40
Not applicableUnknownNCT00429065
What this trial is testing

Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

Who this might be right for
Non-Hodgkin Lymphoma
Instituto Nacional de Cancerologia de Mexico 30
Not applicableStudy completedNCT03677128
What this trial is testing

Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment

Who this might be right for
Burkitt LymphomaRetinoblastomaDiffuse Large B-cell Lymphoma
Duke University 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT02734771
What this trial is testing

Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Patrick Reagan 24
Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Next Page